.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,136,782

« Back to Dashboard

Details for Patent: 6,136,782

Title: Multimeric antithrombotic agents
Abstract:This invention relates to antithrombotic agents and uses thereof. Specifically, the invention relates to chemical moieties that specifically bind to platelets and inhibit their aggregation, including linear and cyclic peptides. The invention provides methods for using these antithrombotic agents to prevent the formation of thrombi at sites in a mammalian body. In particular, the platelet-specific binding moieties including linear and cyclic peptides of the invention are covalently linked to a polyvalent linker moiety, so that the polyvalent linker moiety is covalently linked to a multiplicity of the platelet-specific binding moieties including linear and cyclic peptides. Efficacious antithrombotic agents are thereby provided.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Apr 20, 1995
Application Number:08/411,625
Claims:1. A multimeric antithrombotic agent comprising:

(a) at least two copies of a platelet binding peptide comprising an amino acid sequence of between about 3 to about 100 amino acids; and

(b) a polyvalent linking moiety which is covalently bonded to each peptide thereby linking said peptides, wherein said peptide has a formula

wherein A is selected from the group consisting of H, an amine protecting group and(aa).sub.p, where (aa).sub.p is a peptide comprising an amino acid sequence of length p, wherein when an amino acid (aa) is cysteine, said cysteine may be protected at a sidechain sulfur atom, and p is an integer from 0 to 97;

R.sup.1 is selected from the group consisting of a lipophilic amino acid and H;

X is an amino acid capable of being positively charged;

(aa).sub.n is a peptide comprising an amino acid sequence of length n, wherein when an amino acid (aa) is cysteine, said cysteine may be protected at a sidechain sulfur atom; n is an integer from 0 to 97;

Z is absent or selected from the group consisting of cysteine, isocysteine and homocysteine;

B is selected from the group consisting of --OH, --NH.sub.2, --SH, and (aa).sub.m, wherein (aa).sub.m is a peptide comprising an amino acid sequence of length m, wherein when an amino acid (aa) is cysteine, said cysteine may be protected at a sidechain sulfur atom, and m is an integer from 0 to 97; and

n+m+p is.ltoreq.97.

2. The agent of claim 1, wherein R.sup.1 is a lipophilic amino acid selected from the group consisting of phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine.

3. The agent of claim 1, wherein X is selected from the group consisting of lysine, homolysine, arginine, homoarginine, and L-{S-(3-aminopropyl)cysteine}.

4. The agent of claim 1, wherein said peptide comprises between 3 and 20 amino acids.

5. The agent of claim 1, wherein when an amino acid (aa) is cysteine, said cysteine may be protected at a sidechain sulfur atom by a protecting group having a formula

wherein R is selected from the group consisting of a lower alkyl having between 1 and 6 carbon atoms, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, and phenyl substituted with lower alkyl, hydroxy, lower alkoxy, carboxy, or lower alkoxycarbonyl.

6. The agent of claim 1, wherein said polyvalent linking moiety comprises at least two identical functional groups, wherein each functional group is capable of covalently bonding to said peptide.

7. The agent of claim 6, wherein said functional groups are selected from the group consisting of a primary amine, a secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

8. The agent of claim 1, wherein said polyvalent linking moiety comprises a branched polyvalent linking moiety.

9. The agent of claim 1, wherein said polyvalent linking moiety is selected from the group consisting of bis-succinimidylmethylether, tris(succinimidylethyl)amine, a derivative of bis-succinimidylmethylether, and a derivative of tris(succinimidylethyl)amine.

10. The agent of claim 1, wherein each peptide is covalently bonded to said polyvalent linking moiety by a functional group selected from the group consisting of a primary amine, a secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

11. The agent of claim 1, wherein said peptide is chemically synthesized in vitro.

12. The agent of claim 11, wherein said peptide is synthesized by solid phase peptide synthesis.

13. A method for preventing thrombosis within a mammalian body comprising the step of administering an effective therapeutic amount of the agent of claim 1 in a pharmaceutical carrier.

14. A multimeric antithrombotic agent comprising:

(a) at least two copies of a platelet binding cyclic peptide comprising a ligand for a platelet GPIIb/IIIa receptor and having an amino acid sequence of between 5 and about 100 amino acids; and

(b) a polyvalent linking moiety which is covalently bonded to each peptide thereby linking said peptides; wherein said peptide has a formula ##STR5## wherein A.sub.D is a lipophilic D-amino acid; X is an amino acid capable of being positively charged;

(aa).sub.n is a peptide comprising an amino acid sequence of length n, wherein when an amino acid (aa) is cysteine, said cysteine may be protected at a sidechain sulfur atom;

n is an integer between 0 and about 95;

Z is absent or selected from the group consisting of cysteine, isocysteine and homocysteine;

B is selected from the group consisting of --OH, --NH.sub.2, --SH, and (aa).sub.m, wherein (aa).sub.m is a peptide having an amino acid sequence of length m, wherein when an amino acid (aa) is cysteine, said cysteine may be protected at a sidechain sulfur atom, and m is an integer between 0 and about 95; and

n+m is.ltoreq.95

wherein said agent has a molecular weight of less than about 20,000 daltons.

15. The agent of claim 14, wherein A.sub.D is selected from the group consisting of phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine.

16. The agent of claim 14, wherein X is selected from the group consisting of lysine, homolysine, arginine, homoarginine and L-{S-(3-aminopropyl)cysteine}.

17. The agent of claim 14, wherein said peptide comprises between 5 and about 20 amino acids.

18. The agent of claim 14, wherein when an amino acid (aa) is cysteine, said cysteine is protected at a sidechain sulfur atom by a protecting group having a formula

wherein R is a l lower alkyl having between 1 and 6 carbon atoms, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, carboxy, or lower alkoxycarbonyl.

19. The agent of claim 14, wherein said polyvalent linking moiety comprises at least two identical functional groups, wherein each functional group is capable of covalently bonding to said peptide.

20. The agent of claim 19, wherein each functional group is selected from the group consisting of a primary amine, a secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

21. The agent of claim 14, wherein the polyvalent linking moiety is a branched polyvalent linking moiety.

22. The agent of claim 14, wherein said polyvalent linking moiety is selected from the group consisting of bis-succinimidylmethylether, tris(succinimidylethyl)amine, a derivative of bis-succinimidylmethylether, and a derivative of tris(succinimidylethyl)amine.

23. The agent of claim 14, wherein each peptide is covalently bonded to said polyvalent linking moiety by a functional group selected from the group consisting of a primary amine, a secondary amine, a hydroxyl group, a carboxylic acid group and a thiol-reactive group.

24. The agent of claim 1, wherein the peptides are chemically synthesized in vitro.

25. The agent of claim 24, wherein said peptides are synthesized by solid phase peptide synthesis.

26. A composition of matter having the formula

or

27. A method for preventing thrombosis within a mammalian body comprising the step of administering an effective therapeutic amount of the agent of claim 14 in a pharmaceutical carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc